Suppr超能文献

单用低剂量人绒毛膜促性腺激素完成控制性卵巢刺激的疗效

Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation.

作者信息

Filicori Marco, Cognigni Graciela Estela, Gamberini Elena, Parmegiani Lodovico, Troilo Enzo, Roset Brunilde

机构信息

Reproductive Endocrinology Center, University of Bologna, Bologna, Italy.

出版信息

Fertil Steril. 2005 Aug;84(2):394-401. doi: 10.1016/j.fertnstert.2005.02.036.

Abstract

OBJECTIVE

To prove that low-dose hCG alone can be clinically used to replace FSH-containing gonadotropins to complete controlled ovarian hyperstimulation (COH).

DESIGN

Controlled, prospective, randomized study.

SETTING

Academic center.

PATIENT(S): Infertile patients who are candidates for assisted reproduction.

INTERVENTION(S): Patients received [1] recombinant FSH or hMG throughout COH (group A); [2] ovarian priming with recombinant FSH/hMG followed by low-dose hCG (200 IU/day) alone (group B).

MAIN OUTCOME MEASURE(S): Medication consumption; daily serum and follicular fluid (FF) measurements of LH, FSH, hCG, E2, P, T, and androstenedione (A); number and size of follicles; intracytoplasmic sperm injection (ICSI) outcome.

RESULT(S): In group B: [1] duration and dose of recombinant FSH/hMG administration were reduced; [2] preovulatory serum hCG, E2, and T were higher, whereas FSH was lower; [3] FF hCG, E2, T levels, and E2/T, E2/A, and E2/P ratios were higher, whereas A was lower; [4] small but not large preovulatory follicles were reduced; [5] fertilization rates were higher; and [6] serum and FF P levels, and ICSI outcome did not differ.

CONCLUSION(S): Low-dose hCG alone in the late COH stages: [1] reduced recombinant FSH/hMG consumption whereas ICSI outcome was comparable to traditional COH regimens; [2] stimulated follicle growth and maturation independent of FSH administration; [3] was associated with a reduced number of small preovulatory follicles; [4] did not cause premature luteinization; [5] resulted in a more estrogenic intrafollicular environment.

摘要

目的

证明单纯低剂量人绒毛膜促性腺激素(hCG)可在临床上用于替代含促卵泡生成素(FSH)的促性腺激素,以完成控制性卵巢过度刺激(COH)。

设计

对照、前瞻性、随机研究。

地点

学术中心。

患者

适合辅助生殖的不孕患者。

干预措施

患者在整个COH过程中接受[1]重组FSH或人绝经期促性腺激素(hMG)(A组);[2]先用重组FSH/hMG进行卵巢预处理,随后单纯使用低剂量hCG(200 IU/天)(B组)。

主要观察指标

药物消耗;每日血清及卵泡液(FF)中促黄体生成素(LH)、FSH、hCG、雌二醇(E2)、孕酮(P)、睾酮(T)和雄烯二酮(A)的测定;卵泡数量和大小;卵胞浆内单精子注射(ICSI)结局。

结果

在B组中:[1]重组FSH/hMG给药的持续时间和剂量减少;[2]排卵前血清hCG、E2和T较高,而FSH较低;[3]FF中hCG、E2、T水平以及E2/T、E2/A和E2/P比值较高,而A较低;[4]排卵前小卵泡数量减少,但大卵泡数量未减少;[5]受精率较高;[6]血清和FF中P水平以及ICSI结局无差异。

结论

在COH后期单纯使用低剂量hCG:[1]减少了重组FSH/hMG的消耗,而ICSI结局与传统COH方案相当;[2]在不使用FSH的情况下刺激卵泡生长和成熟;[3]与排卵前小卵泡数量减少有关;[4]未导致过早黄素化;[5]导致卵泡内环境雌激素水平更高。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验